{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:26:04Z","timestamp":1793985964970,"version":"4.8.0"},"reference-count":77,"publisher":"Bioscientifica","issue":"11","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The recent development of new medical therapies has transformed the Cushing\u2019s disease and acromegaly management, offering patients more individualized and effective treatment strategies beyond surgery and addressing unmet clinical needs in persistent disease. In Cushing\u2019s disease, newer steroidogenesis inhibitors, pituitary-directed therapies, and glucocorticoid receptor antagonists coupled with increasing recognition of disease heterogeneity have highlighted the importance of individualized therapy selection based on corticotroph adenoma characteristics, severity of hypercortisolism, comorbidities, and patient-specific priorities. Management strategies increasingly focus on normalization of biochemical markers, improvement in quality of life and metabolic outcomes, cardiovascular risk reduction, and prolongation of long-term remission. In acromegaly, the medical treatment landscape has expanded beyond monthly injectable and\/or oral somatostatin receptor ligands and pegvisomant to include newer octreotide formulations, selective oral somatostatin receptor agonists, combination approaches, and a highly targeted growth hormone receptor antagonist. These developments have enabled improved biochemical control, patient convenience, and long-term disease management. Nevertheless, unmet challenges to optimal management include delayed diagnosis, treatment resistance, adverse drug effects, adenoma recurrence, and the burden of chronic disease monitoring. For both disorders, ongoing clinical trials and emerging precision medicine approaches are refining therapeutic algorithms and offering optimism for further improvements in patient outcomes. This review focuses on newly approved and investigational medical treatments for acromegaly and Cushing\u2019s disease and their evolving role in pituitary care.<\/jats:p>","DOI":"10.1530\/erc-26-0317","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:52:56Z","timestamp":1792075976000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["New horizons in pharmacotherapy for Cushing\u2019s disease and acromegaly"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":true,"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[{"name":"Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University 1 , , ,","place":["Portland, Oregon, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-3447","authenticated-orcid":true,"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[{"name":"Pituitary Center, Department of Medicine, Cedars-Sinai Health Sciences University 2 , , ,","place":["Los Angeles, California, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8288-6698","authenticated-orcid":true,"given":"Artak","family":"Labadzhyan","sequence":"additional","affiliation":[{"name":"Pituitary Center, Department of Medicine, Cedars-Sinai Health Sciences University 2 , , ,","place":["Los Angeles, California, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2026110611465637500_bib1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"key":"2026110611465637500_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"key":"2026110611465637500_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41574-023-00868-7","article-title":"An individualized approach to the management of Cushing disease","volume":"19","author":"Fleseriu","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2026110611465637500_bib4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026110611465637500_bib5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026110611465637500_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2023.11305","article-title":"Cushing syndrome: a review","volume":"330","author":"Reincke","year":"2023","journal-title":"JAMA"},{"key":"2026110611465637500_bib7","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","article-title":"Cushing\u2019s syndrome","volume":"402","author":"Gadelha","year":"2023","journal-title":"Lancet"},{"key":"2026110611465637500_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ejendo\/lvaf059","article-title":"Mortality in Cushing\u2019s syndrome: declining over 2 decades but remaining higher than the general population","volume":"192","author":"Akirov","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026110611465637500_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ejendo\/lvag164","article-title":"Metyrapone-associated improvements in health-related quality of life in Cushing\u2019s syndrome","volume":"195","author":"Mezosi","year":"2026","journal-title":"Eur J Endocrinol"},{"key":"2026110611465637500_bib10","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S2213-8587(25)00249-9","article-title":"Cycle characterisation and clinical complications in patients with cyclic Cushing\u2019s syndrome: insights from an international retrospective cohort study","volume":"13","author":"Nowak","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026110611465637500_bib11","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1210\/clinem\/dgag114","article-title":"Acromegaly complications: an update","volume":"111","author":"Giustina","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","article-title":"Consensus on acromegaly therapeutic outcomes: an update","volume":"21","author":"Melmed","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"2026110611465637500_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/13543784.2024.2343056","article-title":"Investigational drugs for the treatment of acromegaly: new agents to transform therapy","volume":"33","author":"Pirchio","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"2026110611465637500_bib14","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1210\/clinem\/dgag152","article-title":"Current treatment landscape of acromegaly","volume":"111","author":"Castinetti","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1210\/endrev\/bnaf020","article-title":"Medical treatment of acromegaly: navigating the present, shaping the future","volume":"46","author":"Gadelha","year":"2025","journal-title":"Endocr Rev"},{"key":"2026110611465637500_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/endrev\/bnaf042","article-title":"Update and practical recommendations for the use of medical treatment of Cushing syndrome","volume":"47","author":"Araujo-Castro","year":"2026","journal-title":"Endocr Rev"},{"key":"2026110611465637500_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2026.102490","article-title":"Prevalence, risk factors and management of bone complications in Cushing\u2019s syndrome across Europe. Data from the European Registry on Cushing\u2019s syndrome (ERCUSYN)","volume":"87","author":"Zdrojowy-Welna","year":"2026","journal-title":"Ann Endocrinol"},{"key":"2026110611465637500_bib18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/ejendo\/lvaf028","article-title":"Impact of remission status in endogenous Cushing\u2019s syndrome on cancer incidence","volume":"192","author":"Rudman","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026110611465637500_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/clinem\/dgaf681","article-title":"The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis","volume":"111","author":"Salvio","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib20","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1210\/clinem\/dgaf206","article-title":"Chronotherapy with once-daily osilodrostat improves cortisol rhythm, quality of life, and sleep in Cushing\u2019s syndrome","volume":"110","author":"Ferrari","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib21","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgag279","article-title":"Consensus on biomarker utility for ACTH-dependent Cushing\u2019s syndrome: a pituitary society modified Delphi panel","author":"Fleseriu","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2021.101490","article-title":"Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome \u2013 a practical guide","volume":"35","author":"Varlamov","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026110611465637500_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1165681","article-title":"Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing\u2019s disease","volume":"14","author":"Feelders","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026110611465637500_bib24","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"key":"2026110611465637500_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"key":"2026110611465637500_bib26","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf118","article-title":"Efficacy and hepatotoxicity during rapid titration of ketoconazole and\/or metyrapone in patients with Cushing syndrome","volume":"9","author":"Elenius","year":"2025","journal-title":"J Endocr Soc"},{"key":"2026110611465637500_bib27","doi-asserted-by":"crossref","first-page":"e1618","DOI":"10.1210\/clinem\/dgaa989","article-title":"Levoketoconazole, the 2S,4R enantiomer of ketoconazole, a new steroidogenesis inhibitor for Cushing\u2019s syndrome treatment","volume":"106","author":"Creemers","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026110611465637500_bib29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","article-title":"Levoketoconazole in the treatment of patients with endogenous Cushing\u2019s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"key":"2026110611465637500_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.595894","article-title":"Levoketoconazole in the treatment of patients with Cushing\u2019s syndrome and diabetes mellitus: results from the SONICS phase 3 study","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026110611465637500_bib31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11102-020-01103-6","article-title":"Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing\u2019s syndrome","volume":"24","author":"Geer","year":"2021","journal-title":"Pituitary"},{"key":"2026110611465637500_bib32","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1530\/EJE-22-0506","article-title":"Levoketoconazole treatment in endogenous Cushing\u2019s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026110611465637500_bib33","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s40618-024-02359-6","article-title":"Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the phase III LINC 3 trial in Cushing\u2019s disease","volume":"47","author":"Pivonello","year":"2024","journal-title":"J Endocrinol Investig"},{"key":"2026110611465637500_bib34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11102-022-01280-6","article-title":"Long-term efficacy and safety of osilodrostat in Cushing\u2019s disease: final results from a phase II study with an optional extension phase (LINC 2)","volume":"25","author":"Fleseriu","year":"2022","journal-title":"Pituitary"},{"key":"2026110611465637500_bib35","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026110611465637500_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11102-024-01471-3","article-title":"Osilodrostat improves blood pressure and glycemic control in patients with Cushing\u2019s disease: a pooled analysis of LINC 3 and LINC 4 studies","volume":"28","author":"Fleseriu","year":"2025","journal-title":"Pituitary"},{"key":"2026110611465637500_bib38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11102-025-01605-1","article-title":"Controlling cortisol excess and comorbidities in Cushing\u2019s syndrome with osilodrostat","volume":"29","author":"Fleseriu","year":"2025","journal-title":"Pituitary"},{"key":"2026110611465637500_bib39","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae201","article-title":"Improved clinical outcomes during long-term osilodrostat treatment of Cushing disease with normalization of late-night salivary cortisol and urinary free cortisol","volume":"9","author":"Newell-Price","year":"2024","journal-title":"J Endocr Soc"},{"key":"2026110611465637500_bib40","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf027","article-title":"Osilodrostat treatment for adrenal and ectopic Cushing syndrome: integration of clinical studies with case presentations","volume":"9","author":"Fleseriu","year":"2025","journal-title":"J Endocr Soc"},{"key":"2026110611465637500_bib41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1507\/endocrj.EJ24-0153","article-title":"Osilodrostat treatment in patients with Cushing\u2019s disease of Asian or non-Asian origin: a pooled analysis of two phase III randomized trials (LINC 3 and LINC 4)","volume":"71","author":"Shimatsu","year":"2024","journal-title":"Endocr J"},{"key":"2026110611465637500_bib42","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/ejendo\/lvaf207","article-title":"Osilodrostat dose impact on efficacy\/safety in Cushing\u2019s disease: large, pooled analysis of LINC 2, 3, and 4","volume":"193","author":"Fleseriu","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026110611465637500_bib43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/cen.70166","article-title":"Impact of osilodrostat on health-related quality of life in Cushing\u2019s disease: analysis of patient-reported outcomes from the phase III LINC 3 and LINC 4 clinical trials","volume":"105","author":"Newell-Price","year":"2026","journal-title":"Clin Endocrinol"},{"key":"2026110611465637500_bib44","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1210\/clinem\/dgaf633","article-title":"Real-world osilodrostat effectiveness and safety in nonpituitary Cushing syndrome","volume":"111","author":"Tabarin","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib45","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf046","article-title":"Osilodrostat treatment of Cushing syndrome in real-world clinical practice: findings from the ILLUSTRATE study","volume":"9","author":"Fleseriu","year":"2025","journal-title":"J Endocr Soc"},{"key":"2026110611465637500_bib46","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgag297","article-title":"Real-world effectiveness and safety of osilodrostat in Cushing\u2019s syndrome: a retrospective phase IV study","author":"Pivonello","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib47","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1210\/clinem\/dgaf552","article-title":"Osilodrostat-associated adrenal gland shrinkage: a case series of patients with ACTH-dependent Cushing\u2019s syndrome","volume":"111","author":"Varlamov","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib48","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1007\/s12325-025-03229-0","article-title":"Matching-adjusted indirect comparison of osilodrostat versus metyrapone for the treatment of Cushing\u2019s syndrome","volume":"42","author":"Hickey","year":"2025","journal-title":"Adv Ther"},{"key":"2026110611465637500_bib49","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib50","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.1287","article-title":"9323 open-label results from grace, a phase 3 double-blind, randomized-withdrawal study of the selective glucocorticoid receptor modulator relacorilant for the treatment of endogenous hypercortisolism (Cushing syndrome)","volume":"8","author":"Pivonello","year":"2024","journal-title":"J Endocr Soc"},{"key":"2026110611465637500_bib51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-8587(25)00362-6","article-title":"Efficacy and safety of relacorilant for the treatment of patients with Cushing\u2019s syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study","volume":"14","author":"Pivonello","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026110611465637500_bib52","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1210\/jc.2015-1606","article-title":"Cyclin E-Mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease","volume":"100","author":"Liu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib53","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/clinem\/dgac588","article-title":"Treatment of Cushing disease with pituitary-targeting seliciclib","volume":"108","author":"Liu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib54","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf149.1471","article-title":"OR12-04 clofutriben, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, vs placebo in a phase II trial for ACTH-dependent Cushing\u2019s syndrome (RESCUE)","volume":"9","author":"Fleseriu","year":"2025","journal-title":"J Endocr Soc"},{"key":"2026110611465637500_bib55","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.114","article-title":"9330 atumelnant (crn04894) induces rapid and sustained reductions in serum and urine cortisol in patients with acth-dependent Cushing syndrome during A phase 1b\/2a, single center, 10-day, inpatient, open-label study","volume":"8","author":"Elenius","year":"2024","journal-title":"J Endocr Soc"},{"key":"2026110611465637500_bib56","first-page":"P920","article-title":"A phase 2, open-label, multiple-ascending-dose trial evaluating anti-ACTH antibody lu AG13909 in adults with Cushing\u2019s disease: balanced trial design","volume":"110","author":"Castinetti","year":"2025","journal-title":"Endocr Abstr"},{"key":"2026110611465637500_bib57","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"2026110611465637500_bib59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2026110611465637500_bib60","doi-asserted-by":"crossref","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","article-title":"IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands","volume":"107","author":"Maione","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib61","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ejendo\/lvaf200","article-title":"Insulin-like growth factor-I and symptoms of acromegaly according to time since somatostatin receptor ligand injection","volume":"193","author":"Remba-Shapiro","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026110611465637500_bib62","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1210\/clinem\/dgae385","article-title":"Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine","volume":"110","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib63","doi-asserted-by":"crossref","first-page":"e1050","DOI":"10.1210\/clinem\/dgaf579","article-title":"Rapid and sustained response of biochemically uncontrolled acromegaly to once-daily oral paltusotine treatment","volume":"111","author":"Biller","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib64","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-026-01733-2","article-title":"Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial","volume":"29","author":"Clemmons","year":"2026","journal-title":"Pituitary"},{"key":"2026110611465637500_bib65","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1210\/clinem\/dgac643","article-title":"ACROBAT edge: safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly","volume":"108","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib66","article-title":"Efficacy and safety of once-daily oral paltusotine in patients with acromegaly: up to 2 years in the PATHFNDR-1 and PATHFNDR-2 open-label extension studies","volume":"10","author":"Gadelha","year":"2026","journal-title":"J Endocr Soc"},{"key":"2026110611465637500_bib67","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/17446651.2024.2363540","article-title":"Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use","volume":"19","author":"Fleseriu","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2026110611465637500_bib68","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","article-title":"Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1","volume":"110","author":"Ferone","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026110611465637500_bib69","first-page":"RC4.4","article-title":"Results from the core phase of the open-label, phase 3 ACROINNOVA 2 trial: CAM2029, a subcutaneous octreotide depot, achieves sustained, long-term biochemical control in acromegaly","volume":"110","author":"Spencer-Segal","year":"2025","journal-title":"Endocr Abstr"},{"key":"2026110611465637500_bib70","first-page":"RC3.4","article-title":"Effect of CAM2029 on long-term biochemical and symptom control in patients with acromegaly according to prior injectable somatostatin receptor ligand","volume":"194","author":"Fleseriu","year":"2026","journal-title":"Eur J Endocrinol"},{"key":"2026110611465637500_bib71","article-title":"CAM2029 octreotide subcutaneous depot maintains biochemical and symptom control across a 4-week dosing interval and for intervals &gt;28 days: data from the ACROINNOVA 2 trial","volume":"194","author":"Gadelha","year":"2026","journal-title":"Eur J Endocrinol"},{"key":"2026110611465637500_bib72","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2026110611465637500_bib73","article-title":"Debio 4126, a new 3-month octreotide formulation, provides sustained release of octreotide, as well as enhanced bioavailability and similar suppression of insulin-like growth factor 1 (IGF-1), compared to monthly Sandostatin LAR in healthy volunteers \u2013 interim results","volume-title":"Presented At: 20th Congress of the European Neuroendocrine Association (ENEA)","author":"Bellon","year":"2022"},{"key":"2026110611465637500_bib74","article-title":"Debio 4126, a new 12-week octreotide formulation, provides maintenance of disease control in patients with acromegaly switching from long-acting somatostatin analogues (SSAs) \u2013 preliminary results","volume-title":"Presented At: 21st Congress of the European Neuroendocrine Association (ENEA)","author":"Ispas-Jouron","year":"2024"},{"key":"2026110611465637500_bib75","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqag090","article-title":"Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly","volume":"167","author":"Kurylo","year":"2026","journal-title":"Endocrinology"},{"key":"2026110611465637500_bib76","article-title":"A first-in-human study of a novel growth hormone receptor antagonist antibody in healthy men demonstrates translational potential for acromegaly","volume":"10","author":"Cummings","year":"2026","journal-title":"J Endocr Soc"},{"key":"2026110611465637500_bib77","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.1155","article-title":"CAM2029, octreotide subcutaneous depot, provides sustained biochemical control of acromegaly: interim results from a phase 3 study (ACROINNOVA 2)","volume":"8","author":"Ferone","year":"2024","journal-title":"J Endocr Soc"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0317\/526568\/erc-26-0317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0317\/526568\/erc-26-0317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:47:11Z","timestamp":1793983631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/11\/e260317\/78386\/New-horizons-in-pharmacotherapy-for-Cushing-s"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-26-0317","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"e260317"}}